Bai Y, Gang B, Zhang M, Wan Z, Liu G, Gu W
Anhui Provincial Key Laboratory of Translational Cancer Medicine, Bengbu Medical University, Bengbu 233000, China.
Department of Biochemistry and Molecular Biology, School of Laboratory Medicine, Bengbu Medical University, Bengbu 233000, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Feb 20;44(2):252-259. doi: 10.12122/j.issn.1673-4254.2024.02.07.
To investigate the protective effect of PF-562271, a FAK inhibitor, against aging platelet-induced injury in human umbilical vein endothelial cells (HUVECs).
Cultured HUVECs were treated with vehicle, lipopolysaccharide (LPS), LPS+aging platelets, or LPS+aging platelets+PF-562271. The changes in protein expressions of FAK, pFAK and PECAM-1 in the treated cells were detected using Western blotting and immunofluorescence assay, and the level of reactive oxygen species (ROS) was detected with flow cytometry. The changes of barrier function of the cells were assessed with cell permeability test and transendothelial cell resistance test. RT-qPCR was used to analyze mRNA expressions of inflammatory factors, and pro-inflammatory cytokine levels in the culture supernatants was determined with enzyme-linked immunosorbent assay. Immunofluorescence assay was used to examine the effect of the ROS inhibitor vitamin C on PECAM-1 expression in the cells with different treatments.
Treatment of HUVECs with LPS and aging platelets significantly increased cellular protein expressions of FAK, pFAK and PECAM-1, which were effectively lowered by addition of PF-562271 ( < 0.05). LPS and aged platelets obviously enhanced ROS production in the cells, which was inhibited by the addition of PF-562271 ( < 0.001). PF-562271 significantly alleviated the damage of endothelial cell barrier function of the cells caused by LPS and aging platelets ( < 0.01). The expressions of TNF-α, IL-6 and IL-8 in HUVECs increased significantly after exposure to LPS and aging platelets, and were obviously lowered after treatment with PF-562271 ( < 0.05). Treatment with vitamin C significantly decreased the expression of PECAM-1 protein in the cells ( < 0.01).
The FAK inhibitor PF-562271 alleviates endothelial cell damage induced by LPS and aging platelets by lowering cellular oxidative stress levels and reducing inflammatory responses.
研究黏着斑激酶(FAK)抑制剂PF-562271对衰老血小板诱导的人脐静脉内皮细胞(HUVECs)损伤的保护作用。
用溶剂、脂多糖(LPS)、LPS+衰老血小板或LPS+衰老血小板+PF-562271处理培养的HUVECs。采用蛋白质免疫印迹法和免疫荧光法检测处理后细胞中FAK、磷酸化FAK(pFAK)和血小板内皮细胞黏附分子-1(PECAM-1)的蛋白表达变化,用流式细胞术检测活性氧(ROS)水平。通过细胞通透性试验和跨内皮电阻试验评估细胞屏障功能的变化。采用逆转录-定量聚合酶链反应(RT-qPCR)分析炎症因子的mRNA表达,用酶联免疫吸附测定法测定培养上清液中促炎细胞因子水平。用免疫荧光法检测ROS抑制剂维生素C对不同处理细胞中PECAM-1表达的影响。
用LPS和衰老血小板处理HUVECs可显著增加细胞中FAK、pFAK和PECAM-1的蛋白表达,添加PF-562271可有效降低这些表达(P<0.05)。LPS和衰老血小板明显增强细胞内ROS的产生,添加PF-562271可抑制这种增强作用(P<0.001)。PF-562271显著减轻LPS和衰老血小板对细胞内皮细胞屏障功能的损伤(P<0.01)。HUVECs暴露于LPS和衰老血小板后,肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和白细胞介素-8(IL-8)的表达显著增加,用PF-562271处理后明显降低(P<0.05)。用维生素C处理可显著降低细胞中PECAM-1蛋白的表达(P<0.01)。
FAK抑制剂PF-562271通过降低细胞氧化应激水平和减轻炎症反应,减轻LPS和衰老血小板诱导的内皮细胞损伤。